- Home
- CCIA vs GNLX Comparison
CCIA vs GNLX Comparison
Compare CCIA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- GNLX
- Stock Information
- Founded
- CCIA N/A
- GNLX 2001
- Country
- CCIA
- GNLX United States
- Employees
- CCIA N/A
- GNLX N/A
- Industry
- CCIA
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- GNLX Health Care
- Exchange
- CCIA Nasdaq
- GNLX Nasdaq
- Market Cap
- CCIA N/A
- GNLX 81.5M
- IPO Year
- CCIA 2023
- GNLX 2023
- Fundamental
- Price
- CCIA $25.74
- GNLX $2.41
- Analyst Decision
- CCIA
- GNLX Strong Buy
- Analyst Count
- CCIA 0
- GNLX 4
- Target Price
- CCIA N/A
- GNLX $18.25
- AVG Volume (30 Days)
- CCIA N/A
- GNLX 103.3K
- Earning Date
- CCIA N/A
- GNLX 11-14-2024
- Dividend Yield
- CCIA N/A
- GNLX N/A
- EPS Growth
- CCIA N/A
- GNLX N/A
- EPS
- CCIA N/A
- GNLX N/A
- Revenue
- CCIA N/A
- GNLX $8,000.00
- Revenue This Year
- CCIA N/A
- GNLX N/A
- Revenue Next Year
- CCIA N/A
- GNLX N/A
- P/E Ratio
- CCIA N/A
- GNLX N/A
- Revenue Growth
- CCIA N/A
- GNLX N/A
- 52 Week Low
- CCIA N/A
- GNLX $1.60
- 52 Week High
- CCIA N/A
- GNLX $14.74
- Technical
- Relative Strength Index (RSI)
- CCIA 43.59
- GNLX 45.99
- Support Level
- CCIA $25.63
- GNLX $2.30
- Resistance Level
- CCIA $25.85
- GNLX $2.53
- Average True Range (ATR)
- CCIA 0.13
- GNLX 0.17
- MACD
- CCIA -0.01
- GNLX 0.01
- Stochastic Oscillator
- CCIA 30.11
- GNLX 54.90
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.